n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Pancreatic Neoplasms

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with Pancreatic Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beijnen, JH; Funahashi, Y; Huitema, AD; Keizer, RJ; Schellens, JH; Semba, T; Wanders, J	1

Trials

1 trial(s) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Pancreatic Neoplasms

Article	Year
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. The AAPS journal, 2011, Volume: 13, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Neoplasm Transplantation; Neoplasms; Nonlinear Dynamics; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome	2011

Article

Year

Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

The AAPS journal, 2011, Volume: 13, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Neoplasm Transplantation; Neoplasms; Nonlinear Dynamics; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome

2011